Its a prime candidate but we need a suitor. I been an investor, employee and a user of Vascepa. This product has changed my entire lipid profile, but the residual effects have been outstanding. I feel better, think clearer and its a great preventative drug in reducing heart attacks. We do not have the indication, but the Jelis study is exactly the Reduce-it study and we hardly eat any fish here, so the results in my opinion once completed will change medicine. Amarin needs to release preliminary data as soon as possible. I go to office that run the clinical trial for Amarin & and the doctors are shocked how well it works. Let's hope for the best.